IL307319A - Compositions and methods for delivery of rna - Google Patents

Compositions and methods for delivery of rna

Info

Publication number
IL307319A
IL307319A IL307319A IL30731923A IL307319A IL 307319 A IL307319 A IL 307319A IL 307319 A IL307319 A IL 307319A IL 30731923 A IL30731923 A IL 30731923A IL 307319 A IL307319 A IL 307319A
Authority
IL
Israel
Prior art keywords
lnp
lipid
molar percentage
composition
dimethyl
Prior art date
Application number
IL307319A
Other languages
English (en)
Hebrew (he)
Original Assignee
Rejuvenation Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenation Tech Inc filed Critical Rejuvenation Tech Inc
Publication of IL307319A publication Critical patent/IL307319A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307319A 2021-03-31 2022-03-30 Compositions and methods for delivery of rna IL307319A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163169118P 2021-03-31 2021-03-31
PCT/US2022/022642 WO2022212576A1 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna

Publications (1)

Publication Number Publication Date
IL307319A true IL307319A (en) 2023-11-01

Family

ID=83456716

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307319A IL307319A (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna

Country Status (8)

Country Link
US (1) US20220347112A1 (cg-RX-API-DMAC10.html)
EP (1) EP4312942A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513048A (cg-RX-API-DMAC10.html)
CN (1) CN117396193A (cg-RX-API-DMAC10.html)
AU (1) AU2022246851A1 (cg-RX-API-DMAC10.html)
CA (1) CA3215112A1 (cg-RX-API-DMAC10.html)
IL (1) IL307319A (cg-RX-API-DMAC10.html)
WO (1) WO2022212576A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771213A (zh) * 2023-01-10 2024-03-29 北京剂泰医药科技有限公司 脂质纳米颗粒组合物及其用途
TW202509222A (zh) * 2023-05-08 2025-03-01 美商默沙東有限責任公司 編碼諾羅病毒vp1抗原之多核苷酸及其用途
WO2025049632A1 (en) * 2023-08-29 2025-03-06 Rejuvenation Technologies Inc. Compositions and methods for broad delivery of rna to tissue
WO2025255027A1 (en) * 2024-06-03 2025-12-11 Flagship Labs 114, Inc. Lipid nanoparticles for topical delivery
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026010842A1 (en) * 2024-07-01 2026-01-08 The Trustees Of The University Of Pennsylvania Use of lipid nanoparticle mrna for tert specific cancer immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525075B2 (en) * 2013-02-22 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Compounds, compositions, methods, and kits relating to telomere extension
IL270631B2 (en) * 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
CA3094057C (en) * 2018-03-27 2025-04-08 Nof Corporation CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CA3124524A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use

Also Published As

Publication number Publication date
CA3215112A1 (en) 2022-10-06
EP4312942A1 (en) 2024-02-07
WO2022212576A1 (en) 2022-10-06
AU2022246851A1 (en) 2023-10-12
JP2024513048A (ja) 2024-03-21
CN117396193A (zh) 2024-01-12
AU2022246851A9 (en) 2023-10-26
EP4312942A4 (en) 2025-03-19
US20220347112A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2024513048A5 (cg-RX-API-DMAC10.html)
JP2025084968A5 (cg-RX-API-DMAC10.html)
US11999675B2 (en) Ionizable cationic lipids
US11547764B2 (en) Lipid nanoparticle compositions and methods for MRNA delivery
JP2024019459A (ja) 切断可能な脂質
EP4467653B1 (en) Improved mrna-loaded lipid nanoparticles and processes of making the same
US10576166B2 (en) Liver specific delivery of messenger RNA
JP2022532213A5 (cg-RX-API-DMAC10.html)
JP2024519715A5 (cg-RX-API-DMAC10.html)
US12594295B2 (en) CFTR mRNA compositions and related methods and uses
US20190185435A1 (en) Stereochemically enriched compositions for delivery of nucleic acids
US20230145188A1 (en) Composition and methods for treatment of methylmalonic acidemia
JP2025090723A5 (cg-RX-API-DMAC10.html)
US20220287966A1 (en) Stable Liquid Lipid Nanoparticle Formulations
RU2021136653A (ru) УЛУЧШЕННЫЙ СПОСОБ ПОЛУЧЕНИЯ ЛИПИДНЫХ НАНОЧАСТИЦ, ЗАГРУЖЕННЫХ мРНК
RU2025110755A (ru) Молекулы рнк, кодирующие rsv-f, и вакцины, содержащие их
RU2025135484A (ru) Способ стабилизации рнк
HK40079866A (en) Lipid nanoparticle compositions and methods for mrna delivery
HK40117439B (en) Improved mrna-loaded lipid nanoparticles and processes of making the same
RU2024116295A (ru) Композиции полинуклеотидов и их применения